Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy

Revisiting and proposing the most important questions in cancer research and clinical oncology

“…By 2018, 101 most important questions have been peer-reviewed and published [3][4][5][6][7][8][9][10][11][12][13][14][15]. These key questions have triggered significant interest in the research fields of cancer etiology [16][17][18][19], epidemiology [20,21], metabolism [22,23], apoptosis [24], senescence [25], angiogenesis [26,27], cachexia [28,29], immunology [30][31][32], treatment resistance [30,33], and novel therapeutic modality [34][35][36][37]. In Figure 1, we present the distribution of the questions categorized into broad topics, some predominantly clinical and others more biological.…”